Latest Conference Articles

Phase 2 research highlights a wellness modality that may improve outcomes in men with prostate cancer.

n a phase 2 study of patients with BCG-unresponsive non–muscle invasive bladder cancer, treatment with recombinant pox-viral vector vaccine Panvac plus bacillus Calmette-Guérin did not significantly improve clinical outcomes.

Administration of direct intramural injection and intravesical instillations of large surface area microparticle docetaxel may be safe and effective in high-risk non-muscle invasive bladder cancer using a particular technique.

Data from the phase 1b ABC study show that the addition of avelumab to BCG induction therapy was safe and well tolerated in patients with BCG-unresponsive non-muscle invasive bladder cancer.

An update from KEYNOTE-365 trial shows the promising efficacy of olaparib in combination with pembrolizumab for patients with post-docetaxel metastatic castration-resistant prostate cancer.

Regardless of prior antiandrogen therapy and its pretreatment duration, enzalutamide plus androgen-deprivation therapy produced clinical benefit over ADT alone in patients with metastatic hormone-sensitive prostate cancer.

Darolutamide has shown an impact on local symptoms in patients with nonmetastatic castration-resistant prostate cancer. One of the impacts was a delay in time to HRQOL deterioration.

Neal Shore, MD, FACS, discusses the use of metastases-free survival as the primary end point in the ARAMIS trial, which looked at darolutamide in men with high-risk non-metastatic castration-resistant prostate cancer (nmCRPC).

Patients with microsatellite instability–high or mismatch repair–deficient prostate cancer may be more likely to respond to treatment with checkpoint inhibitors compared with those who have high tumor mutational burden.

Overall survival in patients with metastatic castration-resistant prostate cancer who are receiving lutetium 177 may be impacted by Cancer and Leukemia Group B prognostic risk group and the receipt of subsequent FDA-approved life-prolonging therapies.

Despite the several classes of drugs either approved, or in development, for the treatment of myeloproliferative neoplasms, a big question remains.

Prospective clinical trial results of lutetium-PSMA suggest the therapy is safe for patients with locally advanced high-risk prostate cancer.

A phase 3 study is underway to evaluate the potential superiority of TAR-200 in combination with cetrelimab to chemoradiotherapy for the treatment of muscle invasive bladder cancer.

Neal Shore, MD, FACS, explains the relationship between the use of darolutamide and control of urinary and bowel adverse events, as observed in an analysis of the phase 3 ARAMIS clinical trial.

Disparities not only are widening among racial groups, but socioeconomic inequities should also be considered and addressed by the wider healthcare community, according to a lymphoma expert.

In the phase 3 HERO trial of relugolix versus standard of care leuprolide in men with advanced prostate cancer, relugolix failed to significantly delay onset of castration resistance.

Patients with BCG-unresponsive, non-muscle invasive bladder cance carcinoma in situ had promising responses to Bacille Calmette-Guérinplus N-803, updated data from cohort A of the phase 2/3 QUILT-3.032 study.

According to secondary analysis results of a phase 3 study, antibody titers and fold changes are possibly predictive of nadofaragene firadenovec efficacy in patients with bacillus Calmette-Guérun unresponsive non-muscle invasive bladder cancer.

Real-world evidence shows robust adherence rates and prostate-specific antigen response to apalutamide in patients with nonmetastatic castration-resistant prostate cancer.

High adherence rates and favorable prostate-specific antigen response to apalutamide where seen in Patients with nonmetastatic castration-resistant prostate cancer.

Early data have shown the promise of CD19-directed chimeric antigen receptor T cells for indolent lymphoma treatment, but longer follow-up is needed to determine if these responses represent cures in these historically difficult-to-treat malignancies.

CARTITUDE-1 update shows continued deep and durable response with iltacabtagene autoleucel in patients with heavily pretreated multiple myeloma.

Rituximab with bendamustine lead to superior outcomes compared with than 2 other popular triplet therapies in patients with treatment-naïve Waldenström macroglobulinemia.

Olatoyosi Sobulo Odenike, MD, explored the risk factors for evolution to MPN AP/blast phase, outcomes for current treatment methods, and potential targeted therapies during a presentation.

IGHV and TP53 remain clinical prognostic importance in patients with chronic lymphocytic leukemia, despite many prognostic markers for chemoimmunotherapy losing their clinically relevance in the context of targeted therapies for patients.

The JAK1/JAK2 inhibitor Ruxolitinib has numerous clinical uses for the treatment of polycythemia vera, especially for adult patients who have had an inadequate response to hydroxyurea.

Multiple new targets are being researched for the treatment of chronic lymphocytic leukemia, and experts a particularly excited about novel BTK inhibitors and cellular therapies.

Controlling infection in patients with chronic lymphocytic leukemia who have an increased risk for infection, may be key for improving survival rates.

Data from the phase 1/2 BRUIN clinical trial showed a 62% objective response rate with responses increasing over time.

In the REVEAL study, having high-risk polycythemia vera was associated with lower survival at 4 years compared with low-risk disease.